Asia Pacific Liposome Drug Delivery Market is expected to reach US$ 1,562.92 Mn by 2027

Liposomal Doxorubicin Segment Held Largest Share of Asia Pacific Liposome Drug Delivery Market in 2019

According to The Insight Partners market research study of ‘Asia Pacific Liposome Drug Delivery Market to 2027 – Regional Analysis and Forecast by Product, Technology and Application,’ the Asia Pacific Liposome Drug Delivery market is expected to reach US$ 1,562.92 million in 2027 from US$ 759.81 in 2019. The market is estimated to grow with a CAGR of 9.6% from 2020-2027. . The report provides trends prevailing in the Asia Pacific Liposome Drug Delivery market and the factors driving market along with those that act as hindrances.

Based on product, The Liposome Drug Delivery market is segmented into liposomal doxorubicin, liposomal paclitaxel, liposomal amphotericin B, others. The liposomal doxorubicin segment held the largest share of the market in 2019, whereas the liposomal amphotericin B segment is anticipated to register the highest CAGR in the market during the forecast period. The drug is commonly used in the treatment of ovarian cancer, breast cancer, multiple myeloma and Kaposi’s sarcoma. The increasing incidence of breast cancer is likely to account for the growth of the liposomal doxorubicin market. Liposomal doxorubicin is usually injected in the bloodstream of the patients. The drug is not available in the pill form and the increasing adoption towards non-invasive drug delivery systems may confine the consumption of the drug. However, the low risk of side effects from the drug and the efficacy of the drug to recover cancer patients are likely to keep up the demand of the drug over the coming years. However, liposomal amphotericin B segment is anticipated to register the highest CAGR in the market during the forecast period. Liposomal amphotericin B refers to a unique lipid formulation of amphotericin B. The drug therapy is used as a standard care for a wide range of medically important opportunistic fungal pathogens. The drug is administered among patients that are unable to tolerate regular amphotericin treatment. Some of the fungal infections treated with the help of liposomal amphotericin B include cryptococcal meningitis and visceral leishmaniasis usually affecting spleen, liver and bone marrow.

The growth of the market is attributed to the some key driving factors such as high incidence of chronic diseases amongst the population, an upsurge in need for non-invasive drug delivery solutions, increasing investments in R&D for pharmaceutical companies. However, high expense involved in the development of drug delivery systems is expected to obstruct the growth of the market to a certain extent during the forecast years

JOHNSON AND JOHNSON SERVICES, INC., LUYE PHARMA GROUP, TAKEDA PHARMACEUTICAL COMPANY LIMITED, Novartis AGare among the leading companies operating in the Asia Pacific Liposome Drug Delivery market. 

ASIA PACIFIC LIPOSOME DRUG DELIVERY MARKET SEGMENTATION

By Product

• Liposomal Doxorubicin
• Liposomal Paclitaxel
• Liposomal Amphotericin B
• Others

By Technology

• Stealth Liposome Technology
• Non-PEGylated Liposome Technology
• DepoFoam Liposome Technology
• Lysolipid Thermally Sensitive Liposome (LTSL) Technology

By Application

• Fungal Diseases
• Cancer Therapy
• Pain Management
• Viral Vaccines
• Photodynamic Therapy

By Country

• China
• Japan
• India
• South Korea
• Australia